U.S. Stock Futures Dip, Novo Nordisk Surges on Weight-Loss Drug Trial Results
1. U.S. Stock Futures Signal Lower Open
- Key indexes near all-time highs on earnings and Trump comments.
- S&P 500, Nasdaq, and Dow futures point downward.
2. Novo Nordisk Stock Skyrockets on Weight-Loss Drug Trial
- Ozempic and Wegovy maker reports positive Phase 1b/2a results.
- Amycretin shows 22% weight loss with once-weekly injection.
3. Boeing Stock Drops on Wider-Than-Expected Loss Forecast
- Plane manufacturer projects $5.46 per share loss, surpassing estimates.
- Revenue at $15.2 billion, below analyst projections.
4. American Express Q4 Results Align with Estimates
- Credit card giant reports quarterly income and revenue largely in line with expectations.
- CEO cites increased spending during the holiday season.
5. Verizon Outperforms Q4 Estimates on Subscriber Growth
- Reports net income and revenue above consensus forecasts.
- Adds 568,000 wireless and 408,000 broadband customers.